Select Issuer Clients

Select Issuer Clients

Issuer Client Profile

Adgero Biopharmaceuticals Holdings

Adgero Biopharmaceuticals, Inc. is a privately-held biopharmaceutical company focused on building a robust pipeline by advancing its proprietary late stage photodynamic therapy ("PDT") platform with broad utility for the treatment of serious oncology indications. Its lead product candidate, REM-001 Therapy, has demonstrated promising safety and efficacy in four Phase 2/3 clinical studies in patients with cutaneous (skin surface) metastatic breast cancer ("CMBC") who have failed radiation therapy. Use of Adgero's existing data or the completion of a Phase 3 trial in individuals with CMBC could lead to approval of REM-001 Therapy.

View Website

Issuer Client News Feed

For Investors

Want to take part in the next big idea?

Join Our Network

For Entrepreneurs

Want to explore how we add value?

Submit Your Business Plan